An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

Clinical trial NCT05225844 · UNKNOWN

Trial details

NCT number: NCT05225844
Sponsor: Harbin Medical University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Gastrointestinal Cancer Immunotherapy Targeted Therapy

Start date: 2019-01-01
Primary completion: 2022-02-01
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.